CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV
07 oct. 2021 06h01 HE
|
CytoDyn Inc.
New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with...
CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research
07 oct. 2021 06h00 HE
|
CytoDyn Inc.
All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan VANCOUVER,...
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A
13 sept. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms
09 sept. 2021 20h30 HE
|
CytoDyn Inc.
An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:...
CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials
02 sept. 2021 18h40 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs
26 août 2021 17h02 HE
|
CytoDyn Inc.
Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led...
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
25 août 2021 08h00 HE
|
CytoDyn Inc.
Decreases in Circulating Tumor Cells after leronlimab induction were seen in 73% of the patients and associated with increase in PFS and OS CytoDyn plans to update its Breakthrough Therapy...
CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report
13 août 2021 06h00 HE
|
CytoDyn Inc.
Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission CMC and Non-Clinical Sections Will Be Fully Resubmitted as Early as September 2021 VANCOUVER,...
CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials
19 juil. 2021 16h41 HE
|
CytoDyn Inc.
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis
19 juil. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...